Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522193 | 1.00 | CHRM1 (0.49) | CHRM1CHRM2CHRM3GPR119SSTR4 | |
| SCHEMBL3522194 | 1.00 | CHRM1 (0.49) | CHRM1CHRM2CHRM3GPR119SSTR4 | |
| SCHEMBL3525042 | 0.87 | CHRM2 (0.48) | CHRM1CHRM2CHRM3GPR119SSTR4 | |
| SCHEMBL3525044 | 0.87 | CHRM2 (0.48) | CHRM1CHRM2CHRM3GPR119SSTR4 | |
| SCHEMBL27158422 | 0.84 | CHRM2 (0.52) | CHRM1CHRM2CHRM3GPR119HSD11B1 | |
| SCHEMBL12094626 | 0.84 | CHRM2 (0.52) | CHRM1CHRM2CHRM3GPR119HSD11B1 | |
| SCHEMBL30988946 | 0.83 | KDM4E (0.55) | GPR119 | |
| SCHEMBL3547018 | 0.79 | CHRM1 (0.49) | CHRM1CHRM2CHRM3GPR119HSD11B1 | |
| SCHEMBL27157756 | 0.79 | RBP4 (0.54) | GPR119 | |
| SCHEMBL3547017 | 0.79 | CHRM1 (0.49) | CHRM1CHRM2CHRM3GPR119HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | CHRM1 135/4885CHRM2 149/4885CHRM3 315/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | CHRM1 135/4885CHRM2 149/4885CHRM3 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.